- Home
- PMO vs TNGX Comparison
PMO vs TNGX Comparison
Compare PMO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMO
- TNGX
- Stock Information
- Founded
- PMO 1993
- TNGX 2014
- Country
- PMO United States
- TNGX United States
- Employees
- PMO N/A
- TNGX N/A
- Industry
- PMO Finance Companies
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PMO Finance
- TNGX Health Care
- Exchange
- PMO Nasdaq
- TNGX Nasdaq
- Market Cap
- PMO 308.4M
- TNGX 317.4M
- IPO Year
- PMO N/A
- TNGX N/A
- Fundamental
- Price
- PMO $10.37
- TNGX $1.95
- Analyst Decision
- PMO
- TNGX Strong Buy
- Analyst Count
- PMO 0
- TNGX 7
- Target Price
- PMO N/A
- TNGX $12.33
- AVG Volume (30 Days)
- PMO 99.0K
- TNGX 817.7K
- Earning Date
- PMO 01-01-0001
- TNGX 05-07-2025
- Dividend Yield
- PMO 4.10%
- TNGX N/A
- EPS Growth
- PMO N/A
- TNGX N/A
- EPS
- PMO 0.42
- TNGX N/A
- Revenue
- PMO N/A
- TNGX $42,069,000.00
- Revenue This Year
- PMO N/A
- TNGX N/A
- Revenue Next Year
- PMO N/A
- TNGX N/A
- P/E Ratio
- PMO $24.38
- TNGX N/A
- Revenue Growth
- PMO N/A
- TNGX 15.17
- 52 Week Low
- PMO $8.57
- TNGX $1.72
- 52 Week High
- PMO $10.68
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- PMO 38.10
- TNGX 37.66
- Support Level
- PMO $10.36
- TNGX $1.80
- Resistance Level
- PMO $10.79
- TNGX $2.01
- Average True Range (ATR)
- PMO 0.11
- TNGX 0.21
- MACD
- PMO -0.04
- TNGX 0.01
- Stochastic Oscillator
- PMO 2.33
- TNGX 31.94
About PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.